Reduced exacerbation frequency and prednisone dose in patients with ABPA and asthma treated with dupilumab

Tjeerd van der Veer; Marloes A Dallinga; Johanna P M van der Valk; Jasper H Kappen; Johannes C C M In 't Veen; Menno M van der Eerden; Gert-Jan Braunstahl

doi:10.1002/clt2.12081

Reduced exacerbation frequency and prednisone dose in patients with ABPA and asthma treated with dupilumab

Clin Transl Allergy. 2021 Dec;11(10):e12081. doi: 10.1002/clt2.12081.

Authors

Tjeerd van der Veer^{1

2}, Marloes A Dallinga¹, Johanna P M van der Valk¹, Jasper H Kappen^{1

3}, Johannes C C M In 't Veen^{1

2}, Menno M van der Eerden², Gert-Jan Braunstahl^{1

2}

Affiliations

¹ Department of Pulmonary Medicine, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.
² Department of Pulmonary Medicine, Erasmus MC, Rotterdam, The Netherlands.
³ Allergy and Clinical Immunology, Immunomodulation and Tolerance Group, Inflammation Repair and Development, Imperial College, National Heart and Lung Institute, London, UK.

No abstract available

Keywords: ABPA; Aspergilosis broncopulmonar alérgica; allergic bronchopulmonary aspergillosis; allergische bronchopulmonale aspergillose; asma; asthma; dupilumab.

Publication types

Letter